Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:OSMT

Osmotica Pharmaceuticals (OSMT) Stock Price, News & Analysis

Osmotica Pharmaceuticals logo

About Osmotica Pharmaceuticals Stock (NASDAQ:OSMT)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.98
$1.49
52-Week Range
N/A
Volume
296,500 shs
Average Volume
396,682 shs
Market Capitalization
$69.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive OSMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Osmotica Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

OSMT Stock News Headlines

Vanda Pharmaceuticals Inc.
RVL Pharmaceuticals PLC (RVLPQ)
Presidential Bombshell: $150T Resource to Be Released as soon as this Summer?
Something extraordinary is happening in Washington. For the first time in over a century, a sitting President could release a national treasure that's been tied up in red tape, for generations. I'm talking about a $150 trillion American asset that's scattered across all 50 states. While the mainstream media focuses on political theater, this story is quietly developing behind closed doors.
What Wall Street expects from Osmotica Pharmaceuticals's earnings
See More Headlines

OSMT Stock Analysis - Frequently Asked Questions

Osmotica Pharmaceuticals plc (NASDAQ:OSMT) posted its quarterly earnings data on Monday, November, 15th. The company reported ($0.42) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by $0.06. The company had revenue of $2.20 million for the quarter, compared to analyst estimates of $2.39 million. Osmotica Pharmaceuticals had a negative net margin of 138.76% and a negative trailing twelve-month return on equity of 81.23%.

Osmotica Pharmaceuticals (OSMT) raised $58 million in an initial public offering on Thursday, October 18th 2018. The company issued 8,300,000 shares at a price of $7.00 per share. Jefferies, Barclays, RBC Capital MarketsWells and Fargo Securities acted as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Osmotica Pharmaceuticals investors own include Canopy Growth (CGC), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), NIO (NIO), Allena Pharmaceuticals (ALNA) and Endo International (ENDP).

Company Calendar

Last Earnings
11/15/2021
Today
7/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:OSMT
CIK
1739426
Fax
N/A
Employees
302
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($1.59)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$79.59 million
Net Margins
-138.76%
Pretax Margin
-167.59%
Return on Equity
-81.23%
Return on Assets
-20.97%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.43
Quick Ratio
0.42

Sales & Book Value

Annual Sales
$177.88 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
1.00
Book Value
$1.50 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
62,585,000
Free Float
59,318,000
Market Cap
$69.47 million
Optionable
Not Optionable
Beta
2.34
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:OSMT) was last updated on 7/13/2025 by MarketBeat.com Staff
From Our Partners